AAVOLUTION
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

AAVOLUTION Trademark

Serial Number: 98433745

AAVOLUTION is a trademark filed by CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC on March 5, 2024. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC (19 trademarks)

411 SWEDELAND ROAD
KING OF PRUSSIA, PA 19406

Entity Type: 16

Trademark Details

Filing Date

March 5, 2024

Registration Date

Not Registered

Published for Opposition

October 29, 2024

Goods & Services

Research and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services, namely, production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research; research and development in the field of gene therapy acceleration, vector genome copy titers, droplet digital polymerase chain reaction (PCR) and digital polymerase chain reaction (PCR), mass spectrometry, capsid characterization, bioassays, plasmid DNA, and analytics testing in the field of genes and gene therapy

Manufacturing services for others in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals, plasmid DNA production; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jan 12, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jan 12, 2026 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 17, 2025 EXRA
SOU EXTENSION 1 GRANTED
Apr 17, 2025 EX1G
SOU EXTENSION 1 FILED
Apr 16, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 16, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 10, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 29, 2024 NPUB
PUBLISHED FOR OPPOSITION
Oct 29, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 9, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 19, 2024 CNSA
ASSIGNED TO EXAMINER
Sep 18, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 16, 2024 NWOS
NEW APPLICATION ENTERED
Mar 5, 2024 NWAP